Suxia Luo
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 20
- Lung Cancer Research Studies 11
- Colorectal Cancer Treatments and Studies 8
- HER2/EGFR in Cancer Research 8
- Pancreatic and Hepatic Oncology Research 6
- Cancer Research top 2%
- Immunology top 2%
-
- Gastric Cancer Management and Outcomes 20
- Ferroptosis and cancer prognosis 8
- Molecular Biology top 5%
-
- Esophageal Cancer Research and Treatment 12
- Cited by
- OncologyCancer ResearchImmunology
- Journals
- Journal of Clinical Oncology (19 papers)Annals of Translational Medicine (7 papers)Annals of Oncology (6 papers)
- Partner nations
- ChinaUnited StatesItaly
In The Last Decade
Suxia Luo
102 papers receiving 3.5k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 2.0k
- Cancer Research 745
- Immunology 993
- Pulmonary and Respiratory Medicine 793
- Molecular Biology 1.3k
Countries citing papers authored by Suxia Luo
This map shows the geographic impact of Suxia Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suxia Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suxia Luo more than expected).
Fields of papers citing papers by Suxia Luo
This network shows the impact of papers produced by Suxia Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suxia Luo. The network helps show where Suxia Luo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Suxia Luo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 1 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 8 | |
| 7 | 2023 | 8 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 10 | |
| 10 | 2023 | 1 | |
| 11 | 2022 | 3 | |
| 12 | 2021 | 96 | |
| 13 | 2021 | 91 | |
| 14 | 2021 | 6 | |
| 15 | 2020 | 4 | |
| 16 | 2020 | 6 | |
| 17 | 2019 | 31 | |
| 18 | [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98]. | 2017 | 13 |
| 19 | 2017 | 29 | |
| 20 | 2012 | 1 |
About Suxia Luo
Suxia Luo is a scholar working on Oncology, Microbiology and Pulmonary and Respiratory Medicine, having authored 108 papers that have together received 3.5k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (20 papers), Cancer Immunotherapy and Biomarkers (20 papers), Esophageal Cancer Research and Treatment (12 papers), Lung Cancer Research Studies (11 papers), Colorectal Cancer Treatments and Studies (8 papers), Ferroptosis and cancer prognosis (8 papers), HER2/EGFR in Cancer Research (8 papers) and Pancreatic and Hepatic Oncology Research (6 papers). The work is most often cited by research in Oncology (2.0k citations), Cancer Research (745 citations) and Immunology (993 citations). Suxia Luo has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Kongming Wu, Ming Yi, Linping Xu, Shuang Qin, Shengnan Yu, Mengke Niu, Anping Li, Bing Dong, Qian Chu and Ying Jiao. Their work appears in journals such as Journal of Clinical Oncology, Annals of Translational Medicine, Annals of Oncology, Journal of Hematology & Oncology and Experimental Hematology and Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.